Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

NCT01649271 PHASE1 COMPLETED Results posted

The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2 overexpressing metastatic breast cancer.

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE1
Status	COMPLETED
Enrolment	13
Start date	Mon Jul 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Neoplasms
• Stomach Neoplasms

Interventions

• Herceptin
• afatinib
• trastuzumab
• Herceptin
• afatinib
• afatinib

Countries

France